Annexon, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies that inhibit the complement protein C1q to treat neuroinflammatory diseases affecting the brain, eye and peripheral nervous system. The company’s approach aims to block the classical complement pathway at its initiation to reduce inflammation and tissue damage while preserving other immune functions. Its pipeline includes product candidates for Guillain Barre syndrome, geographic…
Annexon, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies that inhibit the complement protein C1q to treat neuroinflammatory diseases affecting the brain, eye and peripheral nervous system. The company’s approach aims to block the classical complement pathway at its initiation to reduce inflammation and tissue damage while preserving other immune functions. Its pipeline includes product candidates for Guillain Barre syndrome, geographic atrophy and autoimmune conditions. The firm leverages more than a decade of research into complement mediated pathology to advance clinical programs.
Annexon, Inc. does not currently market any approved therapies and therefore does not generate product revenue. The company finances its research and development activities through equity offerings, collaboration agreements and potential licensing arrangements. Revenue may arise in the future from sales of its investigational drugs once they receive regulatory approval.
Annexon, Inc. occupies a niche in the biopharmaceutical sector as a developer of upstream complement inhibitors that target C1q, a point of intervention distinct from downstream blockers such as C3 or C5 inhibitors. In Guillain Barre syndrome the company faces investigational therapies from Hansa Biopharma, AstraZeneca Alexion and argenx but currently no approved treatments exist. For geographic atrophy approved competitors include Apellis’s Syfovre and Astellas’s avacincaptad pegol while several early stage programs explore complement modulation. The company’s competitive advantages include its proprietary C1q inhibition platform, orphan drug designations, fast track status and PRIME endorsement from the European Medicines Agency. These positions allow Annexon, Inc. to pursue first in class therapeutic options in areas of high unmet medical need.
Annexon, Inc. intends to serve patients suffering from rare and prevalent neuroimmune disorders including Guillain Barre syndrome, geographic atrophy and autoimmune conditions such as cold agglutinin disease and lupus nephritis. The company serves patients and healthcare providers.